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Revised Guidelines to Preserve Last Effective Treatment Option
In response to recent surveillance data suggesting that the oral antibiotic cefixime is becoming less effective in treating 
gonorrhea, CDC has revised its gonorrhea treatment guidelines to preserve the last available effective treatment option for  
as long as possible. The new guidelines are published in the August 10, 2012 issue of the Morbidity and Mortality Weekly 
Report. In addition to revising its treatment guidelines, CDC is also urging researchers in the public and private sectors to 
step up efforts to develop new treatments for this common but potentially serious sexually transmitted disease (STD).
Gonorrhea Treatment: A Shrinking Arsenal
While antibiotics have long been successfully used to treat gonorrhea, 
the bacteria has eventually grown resistant to every drug ever used 
to treat it, including sulfonamides, penicillin, tetracycline, and most 
recently fluoroquinolones. In 2007, due to widespread drug resistance, 
CDC revised its gonorrhea treatment guidelines to no longer 
recommend fluoroquinolones. This left only one class of antibiotics, 
cephalosporins — which includes the oral antibiotic cefixime and the 
injectable antibiotic ceftriaxone — to effectively treat the disease. 
Now, evidence from CDC’s Gonococcal Isolate Surveillance Project 
(GISP) suggests that cefixime is becoming less effective in treating 
gonorrhea (see sidebar at right). 
To date, no patients have failed treatment with either cefixime or 
ceftriaxone in the United States. However, a small but growing number of 
cefixime treatment failures have been observed in other countries. This 
information, coupled with past experience and the latest U.S. surveillance 
data, suggest that it is only a matter of time before gonorrhea becomes 
resistant to the only remaining treatments currently available. 
Revised Guidelines
CDC’s revised treatment guidelines are designed to ensure that patients 
receive the most effective treatment for gonorrhea. 
   The most significant change in the new guidelines is that CDC 
no longer recommends cefixime as an effective oral treatment 
for gonorrhea, leaving only injectable ceftriaxone to be used in 
combination with one of two oral antibiotics, either azithromycin 
or doxycycline. Ceftriaxone is more potent against gonorrhea than 
cefixime, and when paired with the additional oral antibiotic, might 
slow the emergence of drug resistance by ensuring that gonococcal 
infections are quickly cured and not allowed to spread. 
Trends in Declining Effectiveness of 
Cephalosporins
Since 1986, GISP has routinely monitored 
gonorrhea drug susceptibility — or how 
Neisseria gonorrhoeae responds to antibiotics. 
The project annually collects approximately 
6,000 N. gonorrhoeae samples from men 
with urethral gonorrhea at STD clinics in 
approximately 30 U.S. cities. 
Considering the proportion of samples with 
elevated “minimum inhibitory concentrations” 
(MICs) of cefixime and ceftriaxone, recent 
analyses indicate that higher concentrations 
of cephalosporins are increasingly needed 
to stop the bacteria’s growth in laboratory 
tests. An MIC is the lowest concentration 
of antibiotics needed to stop the bacteria’s 
growth in the laboratory. 
From 2006 through 2011 the percentage of 
samples exhibiting elevated MICs increased 
from:
  0 .1% to 1.4% for cefixime
  0 % to 0.4% for ceftriaxone
These increases were most prominent in 
samples from the western United States and 
from gay and bisexual men nationwide — the 
same geographic and population patterns that 
preceded the emergence of fluoroquinolone 
resistance less than a decade ago. 
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  T o further guard against the threat of drug resistance, providers should closely monitor for ceftriaxone treatment  
failure. According to the new guidelines, patients who have persistent symptoms should be retested with a culture-based 
gonorrhea test, which can identify antibiotic-resistant infections. The patient should return one week after re-treatment 
for another culture test — or “test-of-cure” — to ensure the infection is fully cured.
  T he new guidelines maintain oral cefixime as an alternative treatment option in some instances. If ceftriaxone is 
not readily available, providers may prescribe a dual therapy of cefixime plus either azithromycin or doxycycline. 
Azithromycin may be given alone where there is a severe allergy to cephalosporins. However, if either of these alternative 
regimens is prescribed, providers should perform a test-of-cure one week after treatment. 
While these guidelines are necessary, they may make treatment more challenging for some physicians and patients. Health 
care facilities that may not have previously stocked injectable medications will need to begin carrying ceftriaxone, and all 
patients will need to undergo an injection in order to ensure effective treatment for gonorrhea. Efforts to treat the partners 
of those infected may also be complicated by the change. Every effort should be made to ensure that the sex partners 
of all patients with gonorrhea from the past 60 days are evaluated and treated for gonorrhea with ceftriaxone and either 
azithromycin or doxycycline, if possible, or an alternative treatment, if ceftriaxone cannot be prescribed. If a partner cannot 
be brought in for treatment, physicians may consider expedited partner therapy, or having the patient deliver an oral 
combination regimen consisting of cefixime with azithromycin to their partner. 
About Gonorrhea
Gonorrhea is the second most commonly reported infectious disease in the United States. Although gonorrhea rates 
have dropped significantly in recent years, CDC estimates that more than 800,000 Americans still become infected with 
gonorrhea every year. However, fewer than half of these infections (321,849 in 2011) are diagnosed and reported to CDC. 
The disease is caused by Neisseria gonorrhoeae, a bacterium that is spread primarily through sexual contact with the 
penis, vagina, mouth, or anus. Gonorrhea can also be spread from a mother to her baby during delivery. 
Untreated gonorrhea can cause serious health consequences, including pelvic inflammatory disease that can lead 
to infertility and increase the risk of life-threatening ectopic pregnancy in women. In men, gonorrhea can cause 
epididymitis, a painful condition of the testicles that may lead to infertility if left untreated. Untreated gonorrhea can 
also increase a person’s risk of acquiring or transmitting HIV. 
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Urgent Action Needed 
The revised treatment guidelines may help delay the emergence of cephalosporin-resistant gonorrhea, but they do not solve 
the problem of impending gonorrhea drug resistance. Healthcare providers, state and local health departments, and public 
and private partners can all take important additional steps to address the potential threat of drug-resistant gonorrhea: 
   Healthcare Providers — Physicians and other healthcare providers are on the front lines in the fight against gonorrhea 
and play a critical role in our response. CDC encourages all providers to:
•   Take a sexual history. This will help you know which STDs to test your patient for and at which anatomic sites. 
•   Treat all patients diagnosed with gonorrhea promptly according to CDC’s updated treatment guidelines, including post-
treatment testing to confirm cure when recommended; guidelines available at www.cdc.gov/std/treatment
•   Make every effort to evaluate and treat all patients’ sex partners from the previous 60 days 
•   Obtain cultures to test for decreased susceptibility from any patients with suspected or documented gonorrhea 
treatment failures
•   Report any suspected treatment failure to local or state public health officials within 24 hours, helping to ensure that any 
potential resistance is recognized early
   Health Departments and Laboratories — State and local health departments and other laboratories should enhance 
or rebuild gonorrhea culture capacity so that antibiotic resistance testing can be performed to ensure resistant infections 
are quickly detected and reported. If antibiotic resistance testing cannot be performed locally, facilities should identify 
and partner with other labs that can perform such testing. Health departments should develop local response plans and 
notify CDC of treatment failures immediately. Laboratories should also inform local or state public health officials of any 
isolates with decreased susceptibility to cephalosporins.
   Public and Private Partners — CDC urges scientists and private-sector drug developers to prioritize the identification 
and study of effective new antibiotic treatments for gonorrhea. Currently, there are few new promising gonorrhea 
drugs in the pipeline, and only one clinical trial is under way to examine treating gonorrhea using new combinations 
of existing drugs. While CDC is collaborating with the National Institutes of Health to test new combinations of existing 
antibiotics for the bacteria, it is likely that many different approaches will need to be tested before suitable treatment 
options can be found.
Gonorrhea: Protect Yourself  
It is critical that individuals protect themselves against 
infection. Prevention strategies include:
   Abstinence or mutual monogamy — The surest way 
to avoid transmission of gonorrhea is to abstain from 
sexual intercourse, or to be in a long-term, mutually 
monogamous relationship with a partner who has been 
tested and is known to be uninfected. 
   Condoms — When used consistently and correctly, 
condoms can reduce the risk of transmission  
of gonorrhea. 
   Regular screening — Screening for those at greatest 
risk is critical. CDC recommends that sexually active gay 
and bisexual men and high-risk sexually active women 
be tested for gonorrhea at least once a year. 
   Prompt and effective treatment — Anyone who 
becomes infected should get treated with a ceftriaxone 
injection and either azithromycin or doxycycline right 
away to cure the infection and prevent transmission to 
others. Patients receiving a treatment other than dual 
therapy that includes ceftriaxone should be tested one 
week after completing treatment to confirm that the 
infection has been cured.
If you are a member of the news media and need more information, please visit www.cdc.gov/nchhstp/Newsroom  
or contact the News Media Line at CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention:  
404-639-8895 or NCHHSTPMediaTeam@cdc.gov.    
